Current Report Filing (8-k)
October 14 2020 - 4:43PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current Report
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 10, 2020
Blonder
Tongue Laboratories, Inc.
(Exact
Name of registrant as specified in its charter)
Delaware
|
|
1-14120
|
|
52-1611421
|
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(I.R.S. Employer
Identification No.)
|
One
Jake Brown Road, Old Bridge, New Jersey 08857
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (732) 679-4000
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
symbol(s)
|
|
Name
of each exchange on which registered
|
Common
Stock, par value $.001
|
|
BDR
|
|
NYSE
American
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
of Certain Officers.
On
September 10, 2020 and October 12, 2020, the Board of Directors of Blonder Tongue Laboratories, Inc. (the “Company”)
adopted certain amendments (the "Amendments") to the Company's existing Executive Stock Purchase Plan (the “Plan”).
The Amendments are incorporated in a Second Amended and Restated Executive Stock Purchase Plan and an Amendment No. 1 to Second
Amended and Restated Executive Stock Purchase Plan. The Plan, initially adopted in June 2014 and amended and restated in November
2016, permits executive officers of the Company to elect to purchase shares of Company common stock in lieu of receiving cash
salary payments. The Amendments increase the maximum aggregate number of shares of Company common stock that may be purchased
by all participants from 250,000 to 750,000 shares and amend certain provisions relating to the timing of an executive's election
to receive shares in lieu of cash compensation and the method of calculating the fair market value of such shares. The shares
will be acquired directly from the Company at the fair market value of the Company’s common stock on the date of acquisition,
with the fair market value currently to be determined based on the closing price reported on NYSE American on such date.
The
foregoing summary is not complete and is qualified in its entirety by reference to the Second Amended and Restated Executive Stock
Purchase Plan and Amendment No. 1 to Second Amended and Restated Executive Stock Purchase Plan, which are filed as Exhibit 10.1
and Exhibit 10.2, respectively, to this Current Report on Form 8-K and are incorporated herein by reference.
Item 9.01
Financial Statements and Exhibits
(d)
Exhibits.
The following exhibits are filed herewith:
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
October 14, 2020
|
BLONDER TONGUE LABORATORIES, INC.
|
|
|
|
|
By:
|
/s/ Eric Skolnik
|
|
|
Eric Skolnik
|
|
|
Senior Vice President and Chief Financial Officer
|
2
Blonder Tongue Laborator... (AMEX:BDR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Blonder Tongue Laborator... (AMEX:BDR)
Historical Stock Chart
From Apr 2023 to Apr 2024